Market closed
Prices delayed by at least 15 minutes | Prices updated on 08 May 2025, 18.14 BST | Print

Live UK pricing:

Immupharma PLC (IMM)

ORD 1P
Sell: 2.92p|Buy: 3.09p|Change: 0.14 (-4.65%)

Company profile

ImmuPharma PLC is a drug discovery and development company. The pipeline of the company includes novel peptide-based therapeutics within two therapy areas: autoimmunity & inflammation, and anti-infectives. The company's drug candidate is Lupuzor, which treats lupus, a life-threatening autoimmune disease.

Address

One Bartholomew Close
London
GBR
EC1A 7BL


Telephone

+44 2071524080


Sector 

Healthcare


Major shareholders

NameAmountHolding (%)
Lanstead Capital LP80,590,40416.13
Robert henri Zimmer27,344,5146.57
Luca and Associates AG22,000,0005.28

Key personnel

NamePosition
Dr. Franco Di MuzioNon-Executive Director
Mr. Timothy Paul McCarthyExecutive Director,Chairman and Chief Executive Officer
Mr. Dimitri DimitriouExecutive Director,Chief Executive Officer
Dr. Sanjeev PandyaNon-Executive Director,Senior Independent Director
Dr. Stephane Robert George MeryNon-Executive Director
Mr. Timothy Gary FranklinExecutive Director,Chief Operating Officer
Ms. Lisa BaderoonNon-Executive Director

Activity analysis

Geographical analysis

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2025 AJ Bell. All rights reserved.